Indication

Laryngeal Cancer Stage III

1 clinical trial

1 product

Clinical trial

Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma

Status: Active (not recruiting), Estimated PCD: 2020-01-14

Product